Description: Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Home Page: www.ocutx.com
15 Crosby Drive
Bedford,
MA
01730
United States
Phone:
781 357 4000
Officers
| Name | Title |
|---|---|
| Mr. Donald Notman Jr. | CFO, COO & Principal Accounting Officer |
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer |
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO |
| Dr. Peter K. Jarrett Ph.D. | Chief Technology Officer |
| Mr. William S. Slattery Jr. | Vice President of Investor Relations |
| Mr. William H. Ransone II | Vice President of Global Sales & Marketing |
| Ms. Tracy Smith | Vice President of Human Resources |
| Mr. Steve Meyers | Chief Commercial Officer |
| Dr. Peter K. Kaiser M.D. | Chief Development Officer |
| Mr. Sanjay Nayak MBBS, Ph.D. | Chief Strategy Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.113 |
| Price-to-Sales TTM: | 22.4717 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 267 |